CN109891245B - 自身免疫疾病的诊断、预防和/或治疗 - Google Patents

自身免疫疾病的诊断、预防和/或治疗 Download PDF

Info

Publication number
CN109891245B
CN109891245B CN201780062647.9A CN201780062647A CN109891245B CN 109891245 B CN109891245 B CN 109891245B CN 201780062647 A CN201780062647 A CN 201780062647A CN 109891245 B CN109891245 B CN 109891245B
Authority
CN
China
Prior art keywords
ser
leu
glu
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780062647.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109891245A (zh
Inventor
朱全胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Innovation Immunization Technology Co ltd
Original Assignee
American Innovation Immunization Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Innovation Immunization Technology Co ltd filed Critical American Innovation Immunization Technology Co ltd
Publication of CN109891245A publication Critical patent/CN109891245A/zh
Application granted granted Critical
Publication of CN109891245B publication Critical patent/CN109891245B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780062647.9A 2016-08-12 2017-08-11 自身免疫疾病的诊断、预防和/或治疗 Active CN109891245B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374382P 2016-08-12 2016-08-12
US62/374,382 2016-08-12
PCT/US2017/046626 WO2018031947A1 (en) 2016-08-12 2017-08-11 Diagnosis, prevention, and/or treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
CN109891245A CN109891245A (zh) 2019-06-14
CN109891245B true CN109891245B (zh) 2023-05-05

Family

ID=61163324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062647.9A Active CN109891245B (zh) 2016-08-12 2017-08-11 自身免疫疾病的诊断、预防和/或治疗

Country Status (6)

Country Link
US (3) US11266717B2 (https=)
EP (2) EP3497452B1 (https=)
JP (2) JP7303107B2 (https=)
CN (1) CN109891245B (https=)
ES (1) ES3014985T3 (https=)
WO (1) WO2018031947A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109891245B (zh) * 2016-08-12 2023-05-05 美国创新免疫科技有限公司 自身免疫疾病的诊断、预防和/或治疗
CN112312930A (zh) * 2018-05-02 2021-02-02 宾夕法尼亚大学董事会 磷脂酶a2受体嵌合自身抗体受体t细胞的组合物和方法
WO2020037135A1 (en) 2018-08-15 2020-02-20 Charlesworth M Cristine Methods and materials for identifying and treating membranous nephropathy
EP4010704A1 (en) 2019-08-06 2022-06-15 Euroimmun Medizinische Labordiagnostika AG An improved autoantibody detection assay
EP4031676A4 (en) 2019-09-19 2023-10-25 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating membranous nephropathy
EP4117702A4 (en) * 2020-03-06 2024-03-13 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating membranous nephropathy
CN112111015B (zh) * 2020-09-24 2021-12-07 苏州携创生物技术有限公司 PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用
CN112557670A (zh) * 2020-12-07 2021-03-26 东南大学 一种基于尿液外泌体pla2r检测imn的方法、试剂盒及其应用
BR102021022687A2 (pt) 2020-12-11 2022-06-28 Euroimmun Medizinische Labordiagnostika Ag Método e reagentes para diagnosticar nefropatia membranosa
EP4380963A4 (en) * 2021-08-05 2025-06-04 The Trustees of The University of Pennsylvania Compositions and methods of chimeric autoantibody receptor cells expressing extended phospholipase a2 receptor fragments
CN114588881B (zh) * 2022-03-07 2023-07-18 大连理工大学 免疫吸附剂及其制备方法
WO2023183474A1 (en) * 2022-03-23 2023-09-28 Bodhi Bio Llc Antigen-specific therapy for autoimmune diseases
CN116082517B (zh) * 2022-05-26 2025-08-22 成都地奥制药集团有限公司 融合蛋白及其用途
WO2024147113A1 (en) * 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
CN115951047A (zh) * 2023-02-10 2023-04-11 大连大学 自身免疫性水疱病PBMCs直接免疫荧光诊断试剂盒
EP4709746A1 (en) * 2023-05-08 2026-03-18 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating membranous nephropathy
US20250382348A1 (en) * 2024-06-13 2025-12-18 Astero BioPharma LLC Approaches for the selective depletion of pla2r-specific antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365087A1 (en) * 1988-10-21 1990-04-25 Akzo N.V. Immunotoxins for the treatment or prophylaxis of auto-immune diseases
WO2002009649A2 (en) * 2000-08-01 2002-02-07 The University Of Kansas Cell internalized peptide-drug conjugates
CN102159951A (zh) * 2008-07-18 2011-08-17 波士顿医疗中心有限公司 膜性肾病的诊断

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07278196A (ja) * 1994-04-05 1995-10-24 Shionogi & Co Ltd ヒトｉ型ホスホリパーゼａ２レセプター
ES2618543T3 (es) * 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
EP2145684A3 (en) * 2008-07-14 2013-06-26 Samsung Electronics Co., Ltd. Microfluidic device, sample analyzing method using the same, and dilution ration measuring method
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
FI3467509T3 (fi) * 2011-05-04 2026-02-11 Cellular Tech Ltd Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP3027652A1 (en) * 2013-07-09 2016-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-pla2r antibody and uses thereof
GB201410108D0 (en) * 2014-06-06 2014-07-23 Univ Manchester Peptides, and methods and apparatus utilising same
CN104849452A (zh) * 2015-05-14 2015-08-19 深圳市伯劳特生物制品有限公司 一种pla2r抗体定量检测试纸条及制作、检测方法
CN105510575A (zh) * 2015-12-04 2016-04-20 深圳市伯劳特生物制品有限公司 抗磷脂酶A2受体抗体IgG试剂盒及检测方法
CN109891245B (zh) * 2016-08-12 2023-05-05 美国创新免疫科技有限公司 自身免疫疾病的诊断、预防和/或治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365087A1 (en) * 1988-10-21 1990-04-25 Akzo N.V. Immunotoxins for the treatment or prophylaxis of auto-immune diseases
WO2002009649A2 (en) * 2000-08-01 2002-02-07 The University Of Kansas Cell internalized peptide-drug conjugates
CN102159951A (zh) * 2008-07-18 2011-08-17 波士顿医疗中心有限公司 膜性肾病的诊断

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Antibody–Drug Conjugates for Targeted Cancer Therapy;Victor S. Goldmacher, et al.;《Annual Reports in Medicinal Chemistry》;20121231;第47卷;第3.3部分，表23.1 *
Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris.;C.M.PROBY, ET AL.;《British Journal of Dermatolog》;20001231;第321-330页 *
Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy.;Maryline Fresquet, et al.;《J Am Soc Nephrol》;20141231;表3 *
Identification of the Immunodominant Epitope Region in Phospholipase A 2 Receptor-Mediating Autoantibody Binding in Idiopathic Membranous Nephropathy;Liyo Kao, et al.;《J Am Soc Nephrol》;20141231;第2、4-7页 *
重组Dsg3EC1-2嵌合毒素对寻常型天疱疮外周血T、B淋巴细胞的影响;翟志芳;《中国优秀博硕士论文全文数据库（硕士） 医药卫生科技辑》;20050315(第1期);摘要，第7、28-45页 *

Also Published As

Publication number Publication date
EP4644899A3 (en) 2026-04-08
EP3497452B1 (en) 2025-03-05
US20240252590A1 (en) 2024-08-01
US20190183969A1 (en) 2019-06-20
ES3014985T3 (en) 2025-04-28
EP3497452A1 (en) 2019-06-19
JP2022097596A (ja) 2022-06-30
US20220193188A1 (en) 2022-06-23
EP4644899A2 (en) 2025-11-05
EP3497452C0 (en) 2025-03-05
JP7411718B2 (ja) 2024-01-11
WO2018031947A1 (en) 2018-02-15
JP7303107B2 (ja) 2023-07-04
EP3497452A4 (en) 2020-01-22
JP2019524884A (ja) 2019-09-05
US11266717B2 (en) 2022-03-08
CN109891245A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
CN109891245B (zh) 自身免疫疾病的诊断、预防和/或治疗
TWI862640B (zh) 異質雙環肽複合物
US12404342B2 (en) Conjugates for targeted cell surface editing
JP7663513B2 (ja) 調節された合成遺伝子発現システム
US20160031980A1 (en) Compositions and methods for growth factor modulation
JP2015516813A5 (https=)
JP7090545B2 (ja) Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
US20160271218A1 (en) Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
CA2860678A1 (en) Partial mhc constructs and methods of use
WO2017194941A1 (en) Cd200 mutant and its uses
EP2970417A2 (en) Bh4 stabilized peptides and uses thereof
US20180194807A1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
US20180177842A1 (en) Immune system modulators and compositions
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
WO2022105922A1 (zh) 源自于ssx2抗原的短肽
WO2021026376A1 (en) Composition and use of humoral immune suppressor antagonists for the treatment of humoral immuno-suppressed diseases
JP2026501108A (ja) ソルチリンの標的化
JP2025527370A (ja) ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤
WO2026055429A1 (en) Compositions and methods for modulating inter-alpha-trypsin inhibitor h4 isoform (itih4) activity
CN114630837A (zh) 抗原性多肽及其使用方法
NZ749410B2 (en) Conjugates for targeted cell surface editing

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant